1997
HIV Infection and Cognition in Intravenous Drug Users
Selnes O, Galai N, McArthur J, Cohn S, Royal W, Esposito D, Vlahov D. HIV Infection and Cognition in Intravenous Drug Users. Neurology 1997, 48: 223-230. PMID: 9008522, DOI: 10.1212/wnl.48.1.223.Peer-Reviewed Original ResearchConceptsInjection drug usersSeronegative controlsHIV infectionAntiretroviral therapyClinical symptomsMore symptomsDrug users
1993
Differences in Risk Factors for Human Immunodeficiency Virus Type 1 Seroconversion among Male and Female Intravenous Drug Users
Solomon L, Astemborski J, Warren D, Muñoz A, Cohn S, Vlahov D, Nelson K. Differences in Risk Factors for Human Immunodeficiency Virus Type 1 Seroconversion among Male and Female Intravenous Drug Users. American Journal Of Epidemiology 1993, 137: 892-898. PMID: 8484380, DOI: 10.1093/oxfordjournals.aje.a116750.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman immunodeficiency virus type 1 (HIV-1) seroconversionDrug usersSeronegative controlsRisk factorsFemale intravenous drug usersMale intravenous drug usersSex-specific risk factorsCurrent intravenous drug useHIV-seronegative controlsIntravenous drug useRisk of seroconversionRisk factor dataCase-control studyAge 18 yearsConditional logistic regression techniquesTime of interviewMore sex partnersSeroconversion statusSeroconversion visitHIV seroconversionHIV infectionStudy entrySexual transmissionSeroconversion
1991
Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides.
Viscidi R, Hill P, Li S, Cerny E, Vlahov D, Farzadegan H, Halsey N, Kelen G, Quinn T. Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 1190-8. PMID: 1941526.Peer-Reviewed Original ResearchConceptsEnzyme immunoassayHTLV-IIAntibody reactivityPeptide enzyme immunoassayHTLV-II infectionEpidemiology of HTLVDifferentiation of HTLVMicrotiter plate enzyme immunoassaysPattern of reactivitySeronegative controlsEmergency departmentEnv peptidesPositive seraViral infectionNeurological diseasesHTLVSynthetic peptidesInfectionDrug abuseMajor envelope proteinEnvEnvelope proteinPatientsSerumAntibodies